FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895502017> ?p ?o ?g. }

• W2895502017 endingPage "416.e4" @default.
• W2895502017 startingPage "411" @default.
• W2895502017 abstract "Background Systemic medications are often required for severe atopic dermatitis (AD) refractory to topical therapies. Biologic medications are a recent advancement in the field and a comparison with standard systemic approaches would be beneficial. Objective To compare efficacies of systemic therapies for the treatment of AD. Methods A systematic literature review was performed using Medline, Ovid, and Embase. Randomized controlled trials looking at the efficacy of systemic treatments for AD in adults and children were included. Results A total of 41 studies met criteria and were included in our final analysis. Consistent improvements in Eczema Area and Severity Index and Scoring Atopic Dermatitis were reported with dupilumab and cyclosporine. Phase 2 clinical trials for lebrikizumab and tralokinumab were effective and would benefit from phase 3 trials. No study reported efficacy of biologic medications in pediatric patients; however, cyclosporine improved clinical severity by the greatest amount in this group. Limitations A lack of well controlled comparison studies make direct comparisons between the treatments difficult. Conclusion For treatment of severe AD, the strongest evidence currently exists for dupilumab and cyclosporine at improving clinical disease severity. Further research is required to determine long-term safety and efficacy of biologic medications. Systemic medications are often required for severe atopic dermatitis (AD) refractory to topical therapies. Biologic medications are a recent advancement in the field and a comparison with standard systemic approaches would be beneficial. To compare efficacies of systemic therapies for the treatment of AD. A systematic literature review was performed using Medline, Ovid, and Embase. Randomized controlled trials looking at the efficacy of systemic treatments for AD in adults and children were included. A total of 41 studies met criteria and were included in our final analysis. Consistent improvements in Eczema Area and Severity Index and Scoring Atopic Dermatitis were reported with dupilumab and cyclosporine. Phase 2 clinical trials for lebrikizumab and tralokinumab were effective and would benefit from phase 3 trials. No study reported efficacy of biologic medications in pediatric patients; however, cyclosporine improved clinical severity by the greatest amount in this group. A lack of well controlled comparison studies make direct comparisons between the treatments difficult. For treatment of severe AD, the strongest evidence currently exists for dupilumab and cyclosporine at improving clinical disease severity. Further research is required to determine long-term safety and efficacy of biologic medications." @default.
• W2895502017 created "2018-10-12" @default.
• W2895502017 creator A5006964107 @default.
• W2895502017 creator A5065792993 @default.
• W2895502017 creator A5085279947 @default.
• W2895502017 creator A5088950279 @default.
• W2895502017 date "2019-02-01" @default.
• W2895502017 modified "2023-10-11" @default.
• W2895502017 title "Relative efficacy of systemic treatments for atopic dermatitis" @default.
• W2895502017 cites W1497687130 @default.
• W2895502017 cites W1534948608 @default.
• W2895502017 cites W1565956473 @default.
• W2895502017 cites W1566981860 @default.
• W2895502017 cites W1975231760 @default.
• W2895502017 cites W1975343347 @default.
• W2895502017 cites W1975780852 @default.
• W2895502017 cites W1982061770 @default.
• W2895502017 cites W2006724921 @default.
• W2895502017 cites W2012932483 @default.
• W2895502017 cites W2020615614 @default.
• W2895502017 cites W2025830579 @default.
• W2895502017 cites W2032059780 @default.
• W2895502017 cites W2032676695 @default.
• W2895502017 cites W2038602102 @default.
• W2895502017 cites W2040976653 @default.
• W2895502017 cites W2050243251 @default.
• W2895502017 cites W2064583078 @default.
• W2895502017 cites W2066799230 @default.
• W2895502017 cites W2068060182 @default.
• W2895502017 cites W2069946977 @default.
• W2895502017 cites W2070888650 @default.
• W2895502017 cites W2087649518 @default.
• W2895502017 cites W2093410488 @default.
• W2895502017 cites W2093668721 @default.
• W2895502017 cites W2118630839 @default.
• W2895502017 cites W2122022191 @default.
• W2895502017 cites W2130316168 @default.
• W2895502017 cites W2130835116 @default.
• W2895502017 cites W2143138262 @default.
• W2895502017 cites W2147878311 @default.
• W2895502017 cites W2155965505 @default.
• W2895502017 cites W2168297071 @default.
• W2895502017 cites W2174132185 @default.
• W2895502017 cites W2408885425 @default.
• W2895502017 cites W2432916178 @default.
• W2895502017 cites W2524051065 @default.
• W2895502017 cites W2593200577 @default.
• W2895502017 cites W2601555940 @default.
• W2895502017 cites W2610814011 @default.
• W2895502017 cites W2758887523 @default.
• W2895502017 cites W2764058764 @default.
• W2895502017 cites W2766377124 @default.
• W2895502017 cites W2773928291 @default.
• W2895502017 cites W2783829013 @default.
• W2895502017 cites W2808817707 @default.
• W2895502017 cites W4244363430 @default.
• W2895502017 doi "https://doi.org/10.1016/j.jaad.2018.09.053" @default.
• W2895502017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30296535" @default.
• W2895502017 hasPublicationYear "2019" @default.
• W2895502017 type Work @default.
• W2895502017 sameAs 2895502017 @default.
• W2895502017 citedByCount "27" @default.
• W2895502017 countsByYear W28955020172019 @default.
• W2895502017 countsByYear W28955020172020 @default.
• W2895502017 countsByYear W28955020172021 @default.
• W2895502017 countsByYear W28955020172022 @default.
• W2895502017 countsByYear W28955020172023 @default.
• W2895502017 crossrefType "journal-article" @default.
• W2895502017 hasAuthorship W2895502017A5006964107 @default.
• W2895502017 hasAuthorship W2895502017A5065792993 @default.
• W2895502017 hasAuthorship W2895502017A5085279947 @default.
• W2895502017 hasAuthorship W2895502017A5088950279 @default.
• W2895502017 hasConcept C121332964 @default.
• W2895502017 hasConcept C121608353 @default.
• W2895502017 hasConcept C126322002 @default.
• W2895502017 hasConcept C142424586 @default.
• W2895502017 hasConcept C16005928 @default.
• W2895502017 hasConcept C168563851 @default.
• W2895502017 hasConcept C17744445 @default.
• W2895502017 hasConcept C177713679 @default.
• W2895502017 hasConcept C185926286 @default.
• W2895502017 hasConcept C199539241 @default.
• W2895502017 hasConcept C2776173921 @default.
• W2895502017 hasConcept C2778329239 @default.
• W2895502017 hasConcept C2779134260 @default.
• W2895502017 hasConcept C2779473830 @default.
• W2895502017 hasConcept C2779824493 @default.
• W2895502017 hasConcept C2780501606 @default.
• W2895502017 hasConcept C2780699399 @default.
• W2895502017 hasConcept C530470458 @default.
• W2895502017 hasConcept C535046627 @default.
• W2895502017 hasConcept C71924100 @default.
• W2895502017 hasConcept C87355193 @default.
• W2895502017 hasConceptScore W2895502017C121332964 @default.
• W2895502017 hasConceptScore W2895502017C121608353 @default.
• W2895502017 hasConceptScore W2895502017C126322002 @default.
• W2895502017 hasConceptScore W2895502017C142424586 @default.
• W2895502017 hasConceptScore W2895502017C16005928 @default.

• next